GlassScriptPhysician profile
Robert Marc Zemble
NPI 1124224027
$13,967.47
in general payments reported to CMS, 2019-2025
37 companies · $830 in 2025
The $830 reported for 2025 was more than what a typical Allergy & Immunology (Internal Medicine) provider received nationally (typical 2025 total: $681).
See the full distribution for Allergy & Immunology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,511 · 2020: $1,394 · 2021: $2,055 · 2022: $2,018 · 2023: $2,630 · 2024: $3,529 · 2025: $830.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,435 · Honoraria: $2,174 · Consulting Fee: $1,375 · Education: $6.23.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,434.53 |
| Honoraria | $2,174.00 |
| Consulting Fee | $1,375.00 |
| Education | $6.23 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., INC. | $2,070.95 | 2020-2024 | Takhzyro |
| Blueprint Medicines Corporation | $2,033.77 | 2022-2024 | Ayvakit |
| Csl Behring | $1,816.30 | 2019-2025 | Hizentra, Haegarda, Andembry |
| Astrazeneca Pharmaceuticals LP | $1,319.76 | 2019-2025 | Tezspire, Fasenra, Airsupra |
| Genzyme Corporation | $1,241.92 | 2019-2024 | |
| Glaxosmithkline, LLC. | $903.81 | 2019-2025 | Nucala |
| Regeneron Healthcare Solutions, INC. | $432.91 | 2019-2023 | Dupixent |
| Aimmune Therapeutics, INC. | $425.28 | 2020-2024 | |
| Covis Pharma Gmbh | $375.68 | 2021-2022 | |
| Pfizer INC. | $368.55 | 2019-2023 | |
| Amgen INC. | $356.03 | 2021-2024 | Tezspire |
| Kaleo, INC. | $322.03 | 2019-2023 | Auvi-Q |
| Biocryst US Sales Co., LLC | $321.69 | 2021-2023 | Orladeyo |
| Pharming Healthcare, INC. | $314.01 | 2019-2025 | Ruconest |
| Boehringer Ingelheim Pharmaceuticals, INC. | $218.95 | 2020-2022 |
Show all 37 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Optinose US, INC. | $181.29 | 2019-2023 | |
| Novartis Pharmaceuticals Corporation | $153.17 | 2019-2025 | |
| Shire North American Group INC | $139.58 | 2019 | |
| Ionis Pharmaceuticals, INC. | $124.74 | 2025 | Dawnzera |
| Genentech USA, INC. | $113.31 | 2019-2023 | Xolair |
| Teva Pharmaceuticals USA, INC. | $99.03 | 2019-2021 | |
| Sanofi-Aventis U.S. LLC | $95.20 | 2021-2022 | |
| Ars Pharmaceuticals Operations, INC. | $93.24 | 2025 | Neffy |
| Grifols USA, LLC | $81.89 | 2020-2021 | |
| Alk-Abello, INC | $80.80 | 2019-2023 | Ragwitek, Odactra, Grastek |
| Organon LLC | $44.42 | 2025 | Vtama |
| Merck Sharp & Dohme LLC | $37.62 | 2019-2021 | |
| Circassia INC. | $35.27 | 2019 | |
| Greer Laboratories, INC. | $24.69 | 2019 | |
| Leo Pharma INC. | $24.50 | 2023 | Adbry |
| Octapharma USA, INC. | $23.54 | 2020 | |
| Phadia US INC. | $21.89 | 2020 | |
| Hikma Pharmaceuticals USA | $17.63 | 2023 | Ryaltris |
| Horizon Therapeutics Plc | $14.95 | 2020 | |
| Aytu Biopharma, INC. | $14.55 | 2022 | |
| Biohaven Pharmaceuticals, INC. | $12.42 | 2021 | |
| Bio Products Laboratory USA, INC. | $12.10 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Zemble listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.